



mRNA | circRNA | saRNA | dsRNA | Custom

Product Catalog 2026

CATUG Ready-to-Use Products

- Each product has been fully sequence optimized and screened from multiple variants for the highest expression.
- The quality of each batch is fully controlled with IND-grade release specification and confirmed with multiple analytical methods.
- Oligo-dT or chromatography purification ensures high quality and purity.
- Carefully controlled processes to minimize batch-to-batch variation.
- In-house technology for dsRNA removal dramatically reduces the immunogenicity of RNA therapeutics.
- saRNA products with slight mutations to mitigate immunogenicity were developed based on the VEEV self-replicating system.
- Each catalog product has been greatly tested and validated among academic and industrial clients in a wide range of applications.

Ready-to-Use Product List

Type	Catalog #	CatPure™ RNA	Chemical Modification	Application
mRNA	CT039	Cas9 mRNA	N1mΨ	Gene editing
	CT060	EGFP mRNA	N1mΨ	Reporter gene
	CT072	Fluc mRNA	N1mΨ	Reporter gene
	CT119	mCherry mRNA	N1mΨ	Reporter gene
	CT134	EPO mRNA	N1mΨ	Protein Replacement
	CT151	AaCas12b mRNA	N1mΨ	Gene editing
	CT212	CD19 CAR mRNA	N1mΨ	Cell therapy
	CT222	OVA mRNA	5moU	Antigen
	CT228	Cre mRNA	N1mΨ	Gene editing
	CT229	tdTomato mRNA	N1mΨ	Reporter gene
circRNA	CT223	EGFP circRNA	UTP	Reporter gene
	CT224	Fluc circRNA	UTP	Reporter gene
	CT225	CD19 CAR circRNA	UTP	Cell therapy
saRNA	CT226	EGFP saRNA	5mC	Reporter gene
	CT227	Fluc saRNA	5mC	Reporter gene
	CT235	CD19 CAR saRNA	5mC	Cell therapy
Labeled mRNA	CT060-Cy3	EGFP-Cy3 mRNA	N1mΨ, Cy3-UTP	Reporter gene
	CT119-Cy5	mCherry-Cy5 mRNA	N1mΨ, Cy5-UTP	Reporter gene
dsRNA	CT50000/CT60000	dsRNA hairpin70	UTP, N1mΨ	dsRNA reference
	DS500	dsRNA 500	UTP, N1mΨ	dsRNA reference
	DS1000	dsRNA 1000	UTP, N1mΨ	dsRNA reference
	DS1500	dsRNA 1500	UTP, N1mΨ	dsRNA reference

*We can always add new catalog RNA products to meet clients' needs.

Analytical Methods

Compendial Methods

- Appearance
- pH
- Osmolality
- Particulate Matter
- Bacterial Endotoxin
- Sterility
- Container Integrity

General Methods

- Identification
- Content Uniformity
- Residual Solvent
- Elemental Impurities

mRNA and saRNA specific methods

- Concentration
- Purity/Impurities
- Capping Efficiency
- Tailing%
- PolyA Length Distribution
- Potency
- Residual DNA
- Residual Protein
- dsRNA

Our Data

Cell line	HeLa	Hep3B	A549	293T
mRNA amount				
Bright (20x)				
150ng				
75ng				

Figure 1. EGFP expression results in multiple cell types after cell transfection with EGFP mRNA.




Figure 2. In vivo editing efficiency in mouse liver after IV injection of Cas9 mRNA lipid-LNP.




Figure 3. Fluc mRNA potency in mice measured by in vivo imaging after injection.




Figure 4. EGFP-cy3 mRNA delivered in organoids.




Figure 5. CD19 CAR expression results in 293T after cell transfection with CD19 CAR mRNA, circRNA and saRNA.

About CATUG

CATUG is a boutique one-stop CRDMO empowering the global next-generation therapeutics. Founded in 2021, the company is powered by approximately 200 professionals and state-of-the-art R&D and GMP facilities across Asia, the United States, and Europe. Guided by its four core “F” values — Focus, First, Fast, Flexible—CATUG delivers full-lifecycle support from R&D through global commercialization, providing comprehensive end-to-end solutions across DNA, RNA, (t)LNP, protein, and Fill & Finish (F&F). With quality and efficiency at the core, CATUG bridges cutting-edge science with robust, scalable execution to accelerate clients’ innovative therapies worldwide while ensuring uncompromising quality, regulatory compliance, and speed-to-market.



One-Stop from Idea to Product